Prof. Farzin Farzaneh Bio : Prof. Farzin Farzaneh

CV       Farzin Farzaneh D.Phil., FRCPath., FRSB

             Professor of Molecular Medicine, King’s College London

Date of Birth:                19 August 19, 1953 – Tehran, Iran

Education:

1970    Completion of High School studies (GCSE Examinations) in UK 1973/75 Higher National Diploma at Brighton College of Technology.

1975/76      BSc Developmental Biology, University of Aberdeen.

1976/77       MSc in Biochemistry, University of Aberdeen.

1977/79       PhD in Cell & Molecular Biology, University of Sussex.  

Fellowships:

1979/82           Beit Memorial Fellowship, University of Sussex. 1983             EMBO Fellowship, University of Amsterdam 1984 MRC Fellowships, University of Sussex. 

Academic positions:

1985           Lecturer, King's College London (KCL)

1986-1993 Founded Molecular Genetics Unit, appointed to Senior Lectureship at KCL.

1993-2004 Appointed founding Head of Department of Molecular Medicine, KCL.

1996 -          Personal Chair in Molecular Medicine.

2004 -  Honorary Consultant in Molecular Medicine, Department of Haematological Medicine, King’s College Hospital NHS Trust, London. 

  1. Honorary Consultant, Qualified Person, at the Institute of Child Health, and the

Great Ormond Street Hospital NHS Trust

  1. Qualified Person, BRC GMP Facility at Guy’s & St Thomas’ Hospital NHS Trust

                              

10 most sited publications (>250 Papers with an average of >29 citations each):

  1. Tye GJ, Ioannou K, Amofah E, Quartey-Papafio R, Westrop SJ, Krishnamurthy K, Noble A, Harrison PM, Gaensler KML, Barber LD, Farzaneh F (2015).  The combined molecular adjuvant CASAC enhances the CD8+ T cell response to a tumor-associated self-antigen in aged, immunosenescent mice.  Immunity & Ageing 12:6  doi:10.1186/s12979-015-0033-0
  2. Oppenheim D, Spreafico R, Etuk A, Malone D, Amofah E, Peña-Murillo C, Murray T,

McLaughlin L, SC Beak, Allan S, Belousov A, Passioukov A, Gerdes C, Umaña P, Farzaneh F, Ross PJ (2014).  Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy.  Br J Cancer. 110 (5): 1221-1227. 

  1. Williams GT, Farzaneh F (2012). Are snoRNAs and snoRNA host genes new players in cancer?  Nature Reviews Cancer 12(2): 84-8.
  2. Hardwick N, Chan L, Ingram W, Mufti G, Farzaneh F (2010).  Lytic activity against primary AML cells is stimulated in vitro by an autologous whole cell vaccine expressing IL-2 and CD80.  Cancer Immunol Immunother. 59(3): 379-388.
  3. Ingram W, Chan L, Guven H, Darling D, Kordasti S, Hardwick N, Barber L, Mufti GJ, Farzaneh F (2009).  Human CD80/IL-2 lentivirus transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for immunotherapy. Brit. J. Haematol. 145(6): 749-60.  
  4. McKie AT, Barrow D, Latunde-Dada GO, Rolfs A, Sager G, Mudaly E, Mudaly M, Richardson C, Barlow D, Bomford A, Peters TJ, Raja KB, Shirali S, Hediger MA, Farzaneh F, Simpson RJ (2001).  Iron-regulated ferric reductase associated with the absorption of dietary iron.   Science 291: 1755-1759.
  5. Galea-Lauri J, Darling D, Kuiper M, Gäken J, Souberbielle B & Farzaneh F (1999).  Expression of a variant CD28 on a sub-population of human NK cells:  Implications for B7mediated stimulation of NK cells.  J. Immunology 163: 62-70.
  6. Gäken JA, Tavassoli M, Gan SU, Vallian S, Giddings I, Darling DC, Thomas MG, Schreiber V, Menissier-de Murcia J, Collins MKL, Shall S, Farzaneh F (1996).  Efficient retroviral infection of mammalian cells requires poly(ADP-ribose) polymerase activity.  J. Virol 70; 3992-4000.
  7. Harrison PM, Frezner Degen SJ, Williams R, Farzaneh F (1994).  Hepatic expression of heptocyte-growth-factor/macrophage-stimulating protein mRNA in fulminant hepatic failure.  Lancet 344; 27-28. 
  8. Farzaneh F, Zalin R, Brill D, Shall S (1982).  DNA strand breaks and ADP-ribosyl transferase activation during cell differentiation.  Nature 300; 362-366.

Two edited books on the “The Human Genome: A Functional Analysis” and “Gene Therapy of Cancer”.

List of Major grants received in the last five years

Funding Source

Project title

Coordinator

Duration

Total funding

2010

Roche

Pharmaceuticals.

Analysis of NK cell biology and and induction of ADCC pre-cvlinical and clinical studies

F Farzaneh

2010/2014

£2,553,000

2013

BBSRC

Biotechnology and Biological Sciences Research Council (BBSRC). Development of an enhanced gene specific technology for the isolation of protein binding at a single locus in vivo.  

F Farzaneh, K Ford

2013/2015

£120,000

2012

Northwest

BioTherapeutics

(NWBT)

DCVax for glioblastoma.   

F Farzaneh

2012/2017

£2,966,000

2012

Department    of

Health UK

Department of Health Core Support for Cell & Gene Therapy GMP

Facility

F. Farzaneh

2012/2017

£600,000

2013

Leukaemia

Lymphoma

Research

(Bloodwise)

Pre-emptive immune therapy to prevent relapse of myeloid malignancies.  PIs: Farzin Farzaneh & Linda Barber.  

F Farzaaneh & L Barber

2013/2017

£1,093,000

2014

Cellectis

Pharmaceuticals

Manufacture of lentivirus vectors for allogeneic CAR cell therapy

F Farzaneh

2014/2016

£1,800,000

2015

BBSRC/EPSRC/IB

Catalyst

Large-scale lentiviral vector production.   

F Farzaneh

&      Lucas

Chan

2015/2018

£731,000

2015

I4I, Department of Health (NIHR)

Next generation CAR19 studies. 

F Farzaneh

2015/2019

£959,000

2015

Auolus

Pharmaceuticals

Development of a novel procedure for the rapid manufacture of retroviral vectors. 

F Farzaneh

2015/2016

£900,000

2016

Cell    &     Gene

Therapy Catapult

Development of viral vector industrialisation processes. 

F Farzaneh

2016/2017

£130,000

2016

Cellectis

Pharmaceuticals

Development of lentivirus vectors. 

F Farzaneh

2016/2019

£10,300,000

Total

£22,967,000


View: 408 Time(s)   |   Print: 74 Time(s)   |   Email: 0 Time(s)   |   0 Comment(s)

© 2015 All Rights Reserved | ICIAAI 2017, The Third International Congress of Immunology, Asthma and Allergy

Designed & Developed by : Yektaweb